Drug Profile
Research programme: iodothyronine-based therapeutics - BiPar Sciences
Alternative Names: anti-tubulin agent - BiPar; BSI 301; BSI 302; BSI-300 seriesLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BiPar Sciences
- Class Thyronines
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 21 Oct 2010 Preclinical development is ongoing in USA (unspecified route)
- 05 Jun 2007 Preclinical trials in Solid tumours in USA (unspecified route)